Nanopharmaceuticals LLC

Ordway Research Institute, Inc.

Albany College of Pharmacy

Other

Albany College of Pharmacy and Health Services

Orway Research Institute, Inc.

Albany College of Pharmacy and Health Sciences

Paul J Davis

Shaker Ahmed Mousa

Faith B Davis

Hung-Yun Lin

Maria Alexander-Bridges

Aleck Hercbergs

Huiyu Cao

Gennadi V Glinksy

Gennadi V Glinsky

Shaker A Mousa

Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac&#x2122; or Nanotriac&#x2122;) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.

Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders

A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.

Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Thyroid hormone analogs and methods of use

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof

Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders

Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.

Methods of stimulating fat mobilization using a polymer conjugated polyphenol

Provided herein are compositions and methods for treating cancer by increasing the inhibitory effect of cetuximab on HIF1&#x3b1; expression by administering cetuximab in combination with anti-angiogenic thyroid hormone analogs such as tetrac or triac.

Combination treatment of cancer with cetuximab and tetrac

Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.

Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells

Growing community of inventors

West Sand Lake, NY, United States of America

Paul J Davis